ArticleNeuroimmunomodulation2026
Depressive Symptoms in Obese Individuals Accompanied by Greater Basal Inflammation but Lower Monocyte Inflammatory Responses to LPS: A Quest to Uncover Immunologic Links between Depression and Obesity.
Article in Neuroimmunomodulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionDespite the high prevalence of co-occurring conditions between obesity and depression, the knowledge of the underlying mechanisms remains limited. Given the existing evidence of obesity being an inflammatory condition and the association between elevated inflammation and treatment-resistant depression, investigations to uncover immune pathways underlying the obesity-depression link will shed light on the mechanisms and therapeutic options. We investigated whether depressive symptoms and adiposity are associated with greater inflammation and with suppressed innate immune responses to an immune challenge.
methodsImmune activities and depressive symptoms using the Beck Depression Inventory (BDI) were assessed in 96 participants of a weight range (normal weight, overweight, or obesity). Percent adiposity was measured by dual-energy X-ray absorptiometry. Plasma C-reactive protein (CRP), tumor necrosis factor (TNF), interleukin (IL)-1β, and IL-6 levels were determined by immunoassay. Lipopolysaccharides (LPSs)-stimulated intracellular TNF in peripheral blood monocytes was assessed by flow cytometry, which was also examined after incubation with recombinant TNF (rTNF) in 10 healthy participants of normal body mass index (BMI).
resultsObese, but not overweight, participants showed significantly higher BDI scores (T
conclusionOur findings provide the evidence that greater adiposity is associated with depressive symptoms and that obese individuals even without clinical depression experience elevated depressive symptoms. Whether immunologic dysregulation underlies this depressive mood-adiposity association is inconclusive despite greater CRP and lower monocyte reactivity among the obese, but low-grade inflammation in obesity may contribute to impaired innate immune responses to immunological challenge. Additional mechanistic investigations of obesity-related immune dysregulation underlying mood disorders would inform effective therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.